Literature DB >> 1333078

Picroliv and its components kutkoside and picroside I protect liver against galactosamine-induced damage in rats.

Y Dwivedi1, R Rastogi, N K Garg, B N Dhawan.   

Abstract

D-Galactosamine (800 mg/kg, intraperitoneally) caused significant decrease in the activities of 5'-nucleotidase, glucose-6-phosphatase and cytochrome P450 and increase in activities of gamma-glutamyl transpeptidase, succinate dehydrogenase, acid phosphatase and acid ribonuclease in liver after 24 hr. The levels of RNA, protein and glycogen decreased while total lipids, phospholipids, cholesterol and lipid peroxides increased. It also increased the serum levels of transaminases, alkaline phosphatase and bilirubin while protein concentration decreased significantly. Oral administration of Picroliv (12 mg/kg/day for 7 days), a standardised iridoid glycoside fraction of Picrorhiza kurroa, significantly prevented the biochemical changes in liver and serum of galactosamine-toxicated rats. Kutkoside (12 mg/kg/day for 7 days) also protected against changes in most of the hepatic and serum constituents studied. Another iridoid glycoside from Picroliv, Picroside I, at the same dose level could only prevent toxicant-induced changes in acid phosphatase, phospholipids and lipid peroxides in liver and alkaline phosphatase in serum. Mixture of Picroside I and Kutkoside in the ratio of 1:1.5 at 12 mg/kg dose elicited lesser response than Picroliv.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1333078     DOI: 10.1111/j.1600-0773.1992.tb00566.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  7 in total

1.  Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulator--picroliv.

Authors:  Nishi Shakya; Shraddha A Sane; Suman Gupta
Journal:  Parasitol Res       Date:  2011-01-07       Impact factor: 2.289

2.  Picroliv -- a natural product protects cells and regulates the gene expression during hypoxia/reoxygenation.

Authors:  J P Gaddipati; S Madhavan; G S Sidhu; A K Singh; P Seth; R K Maheshwari
Journal:  Mol Cell Biochem       Date:  1999-04       Impact factor: 3.396

3.  Immunomodulator effect of picroliv and its potential in treatment against resistant Plasmodium yoelii (MDR) infection in mice.

Authors:  Varun Dwivedi; Arif Khan; Azevedo Vasco; Nishat Fatima; Vishal Kumar Soni; Anil Dangi; Shailja Misra-Bhattacharya; Mohammad Owais
Journal:  Pharm Res       Date:  2008-06-13       Impact factor: 4.200

4.  Ayurveda and traditional Chinese medicine: a comparative overview.

Authors:  Bhushan Patwardhan; Dnyaneshwar Warude; P Pushpangadan; Narendra Bhatt
Journal:  Evid Based Complement Alternat Med       Date:  2005-10-27       Impact factor: 2.629

5.  Picrorhiza kurroa Enhances β-Cell Mass Proliferation and Insulin Secretion in Streptozotocin Evoked β-Cell Damage in Rats.

Authors:  Shiv Kumar; Vikram Patial; Sourabh Soni; Supriya Sharma; Kunal Pratap; Dinesh Kumar; Yogendra Padwad
Journal:  Front Pharmacol       Date:  2017-08-22       Impact factor: 5.810

6.  Modular Design of Picroside-II Biosynthesis Deciphered through NGS Transcriptomes and Metabolic Intermediates Analysis in Naturally Variant Chemotypes of a Medicinal Herb, Picrorhiza kurroa.

Authors:  Varun Kumar; Ankush Bansal; Rajinder S Chauhan
Journal:  Front Plant Sci       Date:  2017-04-11       Impact factor: 5.753

7.  An integrative approach to develop computational pipeline for drug-target interaction network analysis.

Authors:  Ankush Bansal; Pulkit Anupam Srivastava; Tiratha Raj Singh
Journal:  Sci Rep       Date:  2018-07-06       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.